Adaptive Biotechnologies (ADPT) Projected to Post Earnings on Thursday

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $42.13 million for the quarter.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.04. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. During the same quarter in the previous year, the business earned ($0.30) earnings per share. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Stock Performance

Shares of Adaptive Biotechnologies stock traded down $0.23 during trading on Tuesday, reaching $7.54. The company's stock had a trading volume of 316,974 shares, compared to its average volume of 1,478,767. Adaptive Biotechnologies has a one year low of $2.56 and a one year high of $9.01. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -6.93 and a beta of 1.73. The business's fifty day moving average price is $7.80 and its 200-day moving average price is $6.81.

Insiders Place Their Bets

In other Adaptive Biotechnologies news, insider Francis Lo sold 20,875 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $6.99, for a total transaction of $145,916.25. Following the completion of the transaction, the insider now owns 332,846 shares in the company, valued at $2,326,593.54. This trade represents a 5.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Hershberg sold 53,000 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $7.59, for a total value of $402,270.00. Following the completion of the sale, the director now owns 69,690 shares in the company, valued at approximately $528,947.10. This represents a 43.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 757,601 shares of company stock worth $6,040,624 over the last 90 days. Corporate insiders own 6.20% of the company's stock.

Analysts Set New Price Targets

ADPT has been the subject of a number of research analyst reports. Piper Sandler reiterated an "overweight" rating and set a $11.00 price target (up from $7.00) on shares of Adaptive Biotechnologies in a report on Thursday, February 20th. Scotiabank increased their price target on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the company a "sector outperform" rating in a report on Thursday, February 13th. Finally, The Goldman Sachs Group upgraded shares of Adaptive Biotechnologies from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $8.00 to $9.00 in a report on Friday, March 21st. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Adaptive Biotechnologies currently has an average rating of "Buy" and an average price target of $9.40.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.